Azienda Socio Sanitaria Territoriale Rhodense
- Address
- Viale Carlo Forlanini 95, 20024 Garbagnate Milanese, Italy
Cardiovascular and Metabolic Research
At Azienda Socio Sanitaria Territoriale Rhodense in Garbagnate Milanese, clinical trial activity focuses on the intersection of cardiovascular diseases and nutritional and metabolic diseases, with a strong emphasis on kidney health in people affected by chronic kidney disease.
- Studies in chronic kidney disease in type 2 diabetes mellitus
- Research on non-diabetic chronic kidney disease
- Trials evaluating whether new treatment approaches can better reduce kidney damage and slow disease progression
This research is designed to assess the effectiveness and safety of therapies aimed at improving kidney outcomes, including combination treatment strategies and add-on therapies compared with current standard care.
Kidney Disease Treatment Studies
The site is also involved in trials exploring whether targeted therapies can better protect kidney function in adults with long-term kidney disease, especially where type 2 diabetes or other non-diabetic causes are present.
- Testing a combination approach to see if it lowers urinary albumin-to-creatinine ratio more effectively than either treatment alone
- Evaluating whether an additional therapy can delay the worsening of kidney disease beyond standard care
- Comparing treatment benefit and safety in populations with diabetic and non-diabetic kidney disease
These studies aim to improve treatment effectiveness and support better long-term management of chronic kidney conditions through more personalized care options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Bayer AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Socio Sanitaria Territoriale Rhodense
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Assessment of Finerenone and Empagliflozin Combination Versus Monotherapy in Chronic Kidney Disease with Type 2 Diabetes | Bayer AG | Phase II | Not Recruiting | May 2022 | Feb 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Finerenone | 2 | Unknown | 2021-10-18 | 2022-05-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.